Fundamental Data for MSHL

Marshall Edwards, Inc. is a US clinical development oncology company and is majority owned by Novogen Limited. Marshall Edwards, Inc. an Australian biotechnology company specializing in the development of a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases. It is a pharmaceutical company dedicated to the field of cancer therapy.

# Employees: 0

Address: 140 Wicks Road,North Ryde,,AUS

Phone: 2113

Fax: 011 61 2 8877 6196

Website: meiinformation@marshalledwardsinc.com

Email: 61 2 9878 8474

Sector: Medical

Industry: MED-DRUGS

Executive Officers

www.marshalledwardsinc.com (Christopher Naughton)

Presi.; C.E.O.; Dir. (David Seaton)

C.F.O.; Sec. (Bryan Williams)

Dir. (Stephen Breckenridge)

Dir. (Paul Nestel,Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 3/31/2008

Next Earnings Date(Expected): 12/2/2009

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	MSHL	Compare to S&P
YTD	2.86 %	-14.87 %
4 Weeks	-9.99 %	-10.96 %
12 Weeks	1.41 %	-4.39 %

Shares Information

Analyst Coverage: N

Avg Volume: 34877

Shares Outstanding: 73M

Market Cap: $0.05B

52 Week High: $1.05

52 Week Low: $0.26

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 MSHL split by factor of 0.020

Earnings Performance

EPS Growth in Last Quarter: -133.33 %

EPS Growth in Last Year: -40.00 %

Sales Growth in Last Quarter: -25.93 %

Sales Growth in Last Quarter: -77.78 %

Financials

Qtr Book Value: $4.13

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 347.980